(Reuters) - The company said it will transfer all rights to the
program, including rights to its pre-clinical compound E10030,
for an upfront cash payment, an equity interest in Ophthotech
and potential future milestone payments and royalties.
Financial terms of the deal were not disclosed.
Read more at Reuters.com Mergers News
program, including rights to its pre-clinical compound E10030,
for an upfront cash payment, an equity interest in Ophthotech
and potential future milestone payments and royalties.
Financial terms of the deal were not disclosed.
Read more at Reuters.com Mergers News
No comments:
Post a Comment